Efficacy and Safety Evaluation of Sevelamer Carbonate Combined with Calcium Carbonate in Children with Chronic Kidney Disease and Hyperphosphatemia

The treatment of hyperphosphatemia in children is of great significance; however, there are currently very few studies investigating the use of sevelamer carbonate for this condition in pediatric patients. This study was conducted to compare the safety and efficacy of calcium carbonate and calcium carbonate combined with sevelamer carbonate in pediatric patients with chronic kidney disease (CKD). Pediatric patients diagnosed with CKD combined with hyperphosphatemia from March 2018 to June 2023 were included in this study. Patients in the sevelamer group received a combination of calcium carbonate and sevelamer carbonate to decrease serum phosphorus levels, while patients in the calcium carbonate group or the control group received only calcium carbonate. The therapeutic effect index included serum phosphorus, serum calcium, intact parathyroid hormone, human albumin, lipoprotein, and alkaline phosphatase levels. A total of 118 children diagnosed with CKD complicated with hyperphosphatemia were included in this study. After 12 weeks of treatment, the serum phosphorus levels of the children in the sevelamer group significantly reduced along with significant changes in low-density lipoprotein (LDL) and total cholesterol levels (P < 0.05). However, there were no significant differences in other indicators. Adverse reactions mainly included the adverse reactions of the digestive system, which occurred in 12 and 9 cases in the control and sevelamer groups, respectively. Sevelamer carbonate combined with calcium carbonate can reduce serum phosphorus levels more efficiently and without serious adverse reactions in children.